The Bacteriophage Medical Research Center at the Catholic University of America is advancing the use of engineered T4 bacteriophages for gene therapy, genome editing, and vaccine development. Their research focuses on T4’s potential as a delivery vehicle for DNA, proteins, and CRISPR systems, as well as a platform for needle-free nasal vaccines targeting diseases such as COVID-19 and influenza. Emphasizing a modular, plug-and-play design, the work builds on decades of structural and mechanistic studies of the T4 phage.
More information is available at t4phagecures.com